Prot #CC-220-SLE-001: A PILOT, PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, STUDY TO EVALUATE EFFICACY, SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND PHARMACOGENETICS OF CC-220 IN SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

Project: Research project

StatusFinished
Effective start/end date4/7/154/7/19

Funding

  • PPD Development (Prot #CC-220-SLE-001)
  • Celgene Corporation (Prot #CC-220-SLE-001)